Oslo, Norway-based Photocure (OSE: PHO) said today that it has received notice from medicines regulator Health Canada approving the product monograph for its Cysview (hexaminolevulinate hydrochloride).
The updated indication now covers non-muscle invasive bladder cancer in general, including detection of carcinoma in situ (CIS), a very aggressive form of bladder tumor that is difficult to detect because of its flat shape.
Cysview is indicated as an adjunct to white-light cystoscopy in the diagnosis and follow up of non-muscle invasive bladder cancer, including carcinoma in situ (CIS), in patients with known or suspected bladder cancer to increase tumor detection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze